APPLICATION influenza virus strains A / 17 / New Caledonia / 99/145 (H1N1) as a donor of attenuation for vaccine strains of live influenza vaccine SUBTYPE N2N2. The vaccine strain of influenza virus A / 17 / CA / 66/4412 (N2N2). The vaccine strain of influenza virus A / 17 / TOKYO / 67/912 (N2N2)

摘要

FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to virology and concerns the influenza virus strain A/17/New Caledonia/99/145 (H1N1) used as an attenuation donor, as well as vaccinating strains A/17/California/66/4412 (H2N2) and A/17/Tokyo/67/912 (H2N2). The presented vaccinating strains are reassortants and produced by crossing the epidemic viruses A/California/1/66 (H2N2) and A/Tokyo/3/67(H2N2) respectively with the strain A/17/New Caledonia/99/145 (H1N1). The presented strains A/17/California/66/4412 (H2N2) and A/17/Tokyo/67/912 (H2N2) are deposited in D. I. Ivanovskiy's Institute of Virology, under Nos. 2650 and 2651 respectively. The reassortants have inherited two genes coding surface virus antigen (haemaglutinin and neuraminidase) from the epidemic viruses A/California/1/66 (H2N2) and A/Tokyo/3/67(H2N2) respectively, and the rest six genes coding nonglycosylated proteins from the attenuation donor A/17/New Caledonia/99/145 (H1N1).EFFECT: presented inventions enable producing the vaccinating strains to be used in preparing the intranasal vaccines.3 cl, 2 tbl